Plain-language summary

This Phase 1 trial is comparing Biopsy, Biospecimen Collection, and other medications against other options for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 2 US locations.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Biopsy (PROCEDURE): Undergo tumor biopsy | Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Computed Tomography (PROCEDURE): Undergo SPECT/CT | Positron Emission Tomography (PROCEDURE): Undergo PET scan | Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter (BIOLOGICAL): Given IV | Single Photon Emission Computed Tomography (PROCEDURE): Undergo SPECT/CT | Cemiplimab (BIOLOGICAL): Given IV | Ruxolitinib (DRUG): Given PO

Drugs / treatments

Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details